Dr Mohamed Bouattour

Specialty

Onco-hepatology (hepatocellular carcinoma, cholangiocarcinoma, rare liver cancers)

Hospital

Hôpital Beaujon (Clichy)

Latest articles

• Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. (Aug 1, 2026)
• Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study. (Jul 6, 2026)
• Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort. (Jun 11, 2026)
• Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma. (Jun 11, 2026)
• Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis. (May 12, 2026)